Page last updated: 2024-08-24

ranolazine and Heart Failure

ranolazine has been researched along with Heart Failure in 52 studies

Research

Studies (52)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	16 (30.77)	29.6817
2010's	32 (61.54)	24.3611
2020's	4 (7.69)	2.80

Authors

Authors	Studies
Abidi, E; Altara, R; Amin, G; Booz, GW; Kaplan, A; Zouein, FA	1
Bai, R; Chang, Y; Guo, T; Jiang, H; Jiang, Y; Lan, F; Li, X; Lu, WJ; Ma, S; Qi, M; Song, Y; Wang, H; Zhang, H; Zhang, S	1
Goliopoulou, A; Kalogeras, K; Katsarou, O; Katsioupa, M; Kourampi, I; Marinos, G; Oikonomou, E; Siasos, G; Theofilis, P; Tousoulis, D; Tsatsaragkou, A; Tsigkou, V; Vavuranakis, M	1
He, XN; Li, H; Wang, GT; Yu, ZQ	1
Chan, SY; Forfia, P; Han, Y; Mazurek, JA; Park, MH; Ramani, G; Vaidya, A; Waxman, AB	1
Bontempi, L; Cerini, M; Curnis, A; Giacopelli, D; Inama, L; Raweh, A; Salghetti, F; Sciatti, E; Vassanelli, F; Villa, C; Vizzardi, E	1
Ahmad, S; Bengel, P; Sossalla, S	1
Dietl, A; Maack, C	1
Karthikeyan, VJ; Mezincescu, A; Nadar, SK	1
Ren, Z; Teng, S; Zhao, K	1
Fukaya, H; Laurita, KR; Piktel, JS; Plummer, BN; Rosenbaum, DS; Wan, X; Wilson, LD	1
Alsina, KM; Chen, C; Duan, Q; He, M; Li, X; Ni, L; Nie, J; Wang, B; Wang, DW; Wehrens, XHT; Wen, Z; Wu, L; Zhou, C	1
Belardinelli, L; Danner, BC; Fischer, TH; Hartmann, N; Hasenfuss, G; Herting, J; Hund, TJ; Maier, LS; Mohler, PJ; Sag, CM; Sossalla, S; Toischer, K; Wagner, S	1
Baio, P; D'Elia, E; Duino, V; Ferrero, P; Fiocca, L; Gavazzi, A; Gori, M; Iacovoni, A; Medolago, G; Senni, M	1
Aistrup, GL; Belardinelli, L; Beussink, L; Chirayil, N; El-Bizri, N; Gupta, DK; Kelly, JE; Misener, S; Mongkolrattanothai, T; Nahhas, A; Ng, J; O'Toole, MJ; Rajamani, S; Reddy, M; Shah, SJ; Shryock, JC; Singh, N; Wasserstrom, JA	1
Bacchini, S; Barbieri, L; Bongo, AS; Cavallino, C; Degiovanni, A; Lazzero, M; Lupi, A; Nardi, F; Rametta, F; Rognoni, A; Veia, A	1
Antzelevitch, C; Barajas-Martínez, H; Belardinelli, L; Burashnikov, A; Cordeiro, JM; Di Diego, JM; Hu, D; Kornreich, BG; Moise, NS; Zygmunt, AC	1
Berrino, L; Cappetta, D; Ciuffreda, LP; De Angelis, A; Donniacuo, M; Esposito, G; Ferraiolo, FA; Piegari, E; Rinaldi, B; Rivellino, A; Rossi, F; Russo, R; Urbanek, K	1
Farber, HW; Finch, KT; Stratton, EA	1
Heggermont, WA; Heymans, S; Papageorgiou, AP; van Bilsen, M	1
Belardinelli, L; Blackburn, B; Gupta, RC; Mishra, S; Rastogi, S; Sabbah, HN; Sharov, VG; Stanley, WC	1
Stone, PH	1
Aass, HC; Aronsen, JM; Brørs, O; Haugen, E; Møller, AS; Mørk, HK; Pedersen, J; Sejersted, OM; Sharikabad, MN; Sjaastad, I	1
Doshi, D; Morrow, JP	1
Mellana, WM; Mohan, D; Palaniswamy, C; Selvaraj, DR	1
Belardinelli, L; Maltsev, VA; Sabbah, HN; Undrovinas, A; Undrovinas, NA	1
Chirkov, YY; Horowitz, JD; Kennedy, JA; Sverdlov, AL	1
Dey, T; Martinez, MW; Nanda, S	1
Brachmann, J; Ritscher, G; Simon Demel, K; Simon, H; Turschner, O	1
Bonaca, MP; Braunwald, E; Kakkar, R; Kohli, P; Kudinova, AY; Lee, RT; Morrow, DA; Murphy, SA; Sabatine, MS; Scirica, BM	1
Custodis, F; Laufs, U	1
Eckardt, L; Vogler, J	1
Maier, LS	2
De Rosa, G; Groppa, F; Iafrate, M; Marzot, F; Padrini, R; Panfili, M; Secco, S	1
Saklani, P; Skanes, A	1
Aiba, T; Begley, MJ; Boström, P; Cantley, LC; Das, S; del Monte, F; Ellinor, PT; Graham, EL; Hessler, K; Knight, AC; Morissette, MR; Ottaviano, FG; Quintero, PA; Rosenberg, M; Rosenzweig, A; Tomaselli, GF; Xiao, C	1
Clauß, C; Eckardt, L; Frommeyer, G; Kaese, S; Milberg, P; Pott, C; Schmidt, M; Stypmann, J	1
Belardinelli, L; Breithardt, G; Eckardt, L; Frommeyer, G; Grundmann, F; Milberg, P; Osada, N; Rajamani, S; Stypmann, J	1
Belardinelli, L; Kumar, K; Nieminen, T; Verrier, RL	1
Blackburn, B; Chandler, MP; Morita, H; Roth, BA; Sabbah, HN; Stanley, WC; Suzuki, G; Wolff, A	1
Maisch, B; Rupp, H; Zarain-Herzberg, A	1
Biesiadecki, BJ; Blackburn, B; Chandler, MP; Chaudhry, P; Mishima, T; Nass, O; Sabbah, HN; Stanley, WC; Suzuki, G; Wolff, A	1
Andreadou, I; Cicchitelli, G; Ferrari, R; Guardigli, G; Merli, E	1
Taegtmeyer, H	1
Dunlap, ME; Ibrahim, OA	1
Belardinelli, L; Sabbah, HN; Undrovinas, AI; Undrovinas, NA	1
Bhandari, B; Subramanian, L	1
Belardinelli, L; Hasenfuss, G; Maier, LS; Rasenack, EC; Ruff, H; Schöndube, FA; Sossalla, S; Tenderich, G; Tirilomis, T; Wagner, S; Weber, SL	1
Hagen, B; Kass, RS; Lederer, WJ; Lindegger, N	1
Clark, AL; Cleland, JG; Coletta, AP; Louis, AA; Manousos, IR	1

Reviews

23 review(s) available for ranolazine and Heart Failure

Article	Year
Role of ranolazine in heart failure: From cellular to clinic perspective. European journal of pharmacology, 2022, Mar-15, Volume: 919 Topics: Heart Failure; Humans; Ranolazine; Sodium Channel Blockers	2022
The Role of Ranolazine in Heart Failure-Current Concepts. The American journal of cardiology, 2023, 12-15, Volume: 209 Topics: Acetanilides; Heart Failure; Humans; Piperazines; Ranolazine; Sodium	2023
Inhibition of Late Sodium Current as an Innovative Antiarrhythmic Strategy. Current heart failure reports, 2017, Volume: 14, Issue:3 Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Heart Failure; Humans; Long QT Syndrome; Ranolazine; Sodium Channel Blockers; Sodium Channels	2017
Targeting Mitochondrial Calcium Handling and Reactive Oxygen Species in Heart Failure. Current heart failure reports, 2017, Volume: 14, Issue:4 Topics: Antioxidants; Benzhydryl Compounds; Calcium; Clonazepam; Glucosides; Heart Failure; Humans; Mitochondria, Heart; Oxidation-Reduction; Oxidative Stress; Ranolazine; Reactive Oxygen Species; Risk Factors; Thiazepines	2017
Ranolazine: A true pluripotent cardiovascular drug or jack of all trades, master of none? Sultan Qaboos University medical journal, 2018, Volume: 18, Issue:1 Topics: Arrhythmias, Cardiac; Cardiovascular Diseases; Heart Failure; Humans; Ranolazine; Sodium Channel Blockers	2018
Ranolazine in heart failure with preserved left ventricular ejection fraction and microvascular dysfunction: case report and literature review. Journal of clinical pharmacology, 2013, Volume: 53, Issue:6 Topics: Acetanilides; Aged; Enzyme Inhibitors; Heart Failure; Humans; Male; Microvessels; Piperazines; Ranolazine; Treatment Outcome; Ventricular Function, Left	2013
Ranolazine: effects on ischemic heart. Recent patents on cardiovascular drug discovery, 2013, Volume: 8, Issue:3 Topics: Acetanilides; Angina, Stable; Animals; Arrhythmias, Cardiac; Clinical Trials as Topic; Diabetes Mellitus; Drug Interactions; Heart Failure; Humans; Myocardial Ischemia; Piperazines; Ranolazine; Sodium Channel Blockers	2013
Metabolic support for the heart: complementary therapy for heart failure? European journal of heart failure, 2016, Volume: 18, Issue:12 Topics: Acetyl-CoA C-Acyltransferase; Cardiovascular Agents; Carnitine; Carnitine O-Palmitoyltransferase; Dichloroacetic Acid; Energy Metabolism; Enzyme Inhibitors; Epoxy Compounds; Fatty Acids; Glucose; Heart Failure; Humans; Myocardium; Myocytes, Cardiac; Oxidation-Reduction; Perhexiline; Ranolazine; Stroke Volume; Trimetazidine	2016
Ranolazine: new paradigm for management of myocardial ischemia, myocardial dysfunction, and arrhythmias. Cardiology clinics, 2008, Volume: 26, Issue:4 Topics: Acetanilides; Angina Pectoris; Animals; Arrhythmias, Cardiac; Cardiomyopathies; Drug Therapy, Combination; Heart Failure; Humans; Myocardial Ischemia; Piperazines; Ranolazine	2008
Potential application of late sodium current blockade in the treatment of heart failure and atrial fibrillation. Reviews in cardiovascular medicine, 2009, Volume: 10 Suppl 1 Topics: Acetanilides; Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Heart Conduction System; Heart Failure; Humans; Myocytes, Cardiac; Piperazines; Ranolazine; Sodium; Sodium Channel Blockers; Sodium Channels; Treatment Outcome	2009
Metabolic modulation: a new therapeutic target in treatment of heart failure. American journal of therapeutics, 2011, Volume: 18, Issue:6 Topics: Acetanilides; Carnitine O-Palmitoyltransferase; Enzyme Inhibitors; Epoxy Compounds; Fatty Acids; Glucose; Heart Failure; Humans; Mitochondria, Heart; Myocytes, Cardiac; Perhexiline; Piperazines; Ranolazine; Trimetazidine; Vasodilator Agents	2011
Modulation of myocardial metabolism: an emerging therapeutic principle. Current opinion in cardiology, 2010, Volume: 25, Issue:4 Topics: Acetanilides; Amiodarone; Cardiovascular Agents; Heart Failure; Humans; Hypertrophy, Left Ventricular; Myocardial Ischemia; Myocardial Perfusion Imaging; Myocardial Reperfusion; Myocardium; Perhexiline; Piperazines; Ranolazine; Trimetazidine; Vasodilator Agents	2010
[New developments in the antiarrhythmic therapy of atrial fibrillation]. Herzschrittmachertherapie & Elektrophysiologie, 2010, Volume: 21, Issue:4 Topics: Acetanilides; Aged; Amiodarone; Animals; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Dronedarone; Drug-Related Side Effects and Adverse Reactions; Drugs, Investigational; Electrocardiography; Heart Atria; Heart Failure; Heart Ventricles; Humans; Piperazines; Potassium Channels; Pyrrolidines; Ranolazine; Sodium Channels; Stroke	2010
[Conservative therapy of patients with stable coronary heart disease]. Herz, 2012, Volume: 37, Issue:1 Topics: Acetanilides; Adrenergic beta-Antagonists; Angina Pectoris; Calcium Channel Blockers; Combined Modality Therapy; Coronary Disease; Drug Incompatibility; Enzyme Inhibitors; Heart Failure; Heart Rate; Humans; Life Style; Myocardial Infarction; Myocardial Revascularization; Nitrates; Piperazines; Ranolazine; Treatment Outcome	2012
Pharmacology of myocardial calcium-handling. Wiener medizinische Wochenschrift (1946), 2012, Volume: 162, Issue:13-14 Topics: Acetanilides; Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Calcium; Calcium Channel Blockers; Cardiomegaly; Cardiotonic Agents; Digitalis Glycosides; Dronedarone; Electrocardiography; Heart Failure; Humans; Ion Channels; Myocardial Contraction; Piperazines; Ranolazine; Signal Transduction; Tachycardia	2012
New treatment options for late Na current, arrhythmias, and diastolic dysfunction. Current heart failure reports, 2012, Volume: 9, Issue:3 Topics: Acetanilides; Action Potentials; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Calcium; Cardiovascular Agents; Cations; Diastole; Enzyme Inhibitors; Heart Failure; Heart Failure, Diastolic; Humans; Myocardial Contraction; NAV1.5 Voltage-Gated Sodium Channel; Piperazines; Ranolazine; Sodium; Sodium-Calcium Exchanger	2012
Novel anti-arrhythmic medications in the treatment of atrial fibrillation. Current cardiology reviews, 2012, Volume: 8, Issue:4 Topics: Acetanilides; Amiodarone; Anisoles; Anti-Arrhythmia Agents; Atrial Fibrillation; Clinical Trials as Topic; Digoxin; Dronedarone; Forecasting; Heart Failure; Humans; Phenethylamines; Piperazines; Pyrrolidines; Ranolazine; Sulfonamides; Technology, Pharmaceutical; Ventricular Dysfunction, Left	2012
Mechanisms of ranolazine's dual protection against atrial and ventricular fibrillation. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2013, Volume: 15, Issue:3 Topics: Acetanilides; Action Potentials; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Coronary Artery Disease; Electrocardiography; Heart Conduction System; Heart Failure; Humans; Myocardial Ischemia; Piperazines; Ranolazine; Sodium; Sodium Channel Blockers; Treatment Outcome; Ventricular Fibrillation	2013
The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure. Herz, 2002, Volume: 27, Issue:7 Topics: Acetanilides; Angina Pectoris; Animals; Calcium; Cardiovascular Agents; Clinical Trials as Topic; Enzyme Inhibitors; Epoxy Compounds; Fatty Acids; Gene Expression; Glucose; Heart Failure; Humans; Hypoglycemic Agents; Methylhydrazines; Myocytes, Cardiac; Oxidation-Reduction; Piperazines; Ranolazine; Rats; Rats, Wistar; Sarcoplasmic Reticulum; Trimetazidine; Up-Regulation; Vasodilator Agents	2002
Metabolic modulation and optimization of energy consumption in heart failure. The Medical clinics of North America, 2003, Volume: 87, Issue:2 Topics: Acetanilides; Cardiac Pacing, Artificial; Cardiotonic Agents; Carnitine; Energy Metabolism; Heart Failure; Humans; Piperazines; Ranolazine; Trimetazidine	2003
Combination pharmacologic therapies for heart failure: what next after angiotensin-converting enzyme inhibitors and beta-blockers? Current heart failure reports, 2005, Volume: 2, Issue:2 Topics: Acetanilides; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Clinical Trials as Topic; Drug Therapy, Combination; Enzyme Inhibitors; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Mineralocorticoid Receptor Antagonists; Piperazines; Pyridines; Ranolazine; Tetrazoles; Tolvaptan; Vasodilator Agents	2005
Ranolazine, a partial fatty acid oxidation inhibitor, its potential benefit in angina and other cardiovascular disorders. Recent patents on cardiovascular drug discovery, 2007, Volume: 2, Issue:1 Topics: Acetanilides; Angina Pectoris; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Fatty Acids; Heart Failure; Humans; Oxidation-Reduction; Piperazines; Ranolazine	2007
Clinical trials update: The Heart Protection Study, IONA, CARISA, ENRICHD, ACUTE, ALIVE, MADIT II and REMATCH. Impact Of Nicorandil on Angina. Combination Assessment of Ranolazine In Stable Angina. ENhancing Recovery In Coronary Heart Disease patients. As European journal of heart failure, 2002, Volume: 4, Issue:1 Topics: Acetanilides; Angina Pectoris; Arrhythmias, Cardiac; Cardiology; Clinical Trials as Topic; Comorbidity; Coronary Disease; Defibrillators, Implantable; Depressive Disorder; Electric Countershock; Female; Heart Failure; Humans; Male; Nicorandil; Piperazines; Ranolazine; Sensitivity and Specificity	2002

Trials

1 trial(s) available for ranolazine and Heart Failure

Article	Year
Ranolazine Improves Right Ventricular Function in Patients With Precapillary Pulmonary Hypertension: Results From a Double-Blind, Randomized, Placebo-Controlled Trial. Journal of cardiac failure, 2021, Volume: 27, Issue:2 Topics: Heart Failure; Humans; Hypertension, Pulmonary; Quality of Life; Ranolazine; Stroke Volume; Ventricular Dysfunction, Right; Ventricular Function, Right	2021

Other Studies

28 other study(ies) available for ranolazine and Heart Failure

Article	Year
Ranolazine rescues the heart failure phenotype of PLN-deficient human pluripotent stem cell-derived cardiomyocytes. Stem cell reports, 2022, 04-12, Volume: 17, Issue:4 Topics: Animals; Calcium; Calcium-Binding Proteins; Heart Failure; Humans; Induced Pluripotent Stem Cells; Mice; Myocytes, Cardiac; Phenotype; Pluripotent Stem Cells; Ranolazine	2022
Effects of ranolazine on cardiac function in rats with heart failure. European review for medical and pharmacological sciences, 2019, Volume: 23, Issue:21 Topics: Animals; Apoptosis; Cardiovascular Agents; Cells, Cultured; Disease Models, Animal; Heart Failure; Injections, Intraperitoneal; Male; Ranolazine; Rats; Rats, Wistar	2019
Ranolazine therapy in drug-refractory ventricular arrhythmias. Journal of cardiovascular medicine (Hagerstown, Md.), 2017, Volume: 18, Issue:7 Topics: Aged; Anti-Arrhythmia Agents; Defibrillators, Implantable; Disease Progression; Drug Resistance; Electric Countershock; Female; Heart Failure; Humans; Male; Middle Aged; Ranolazine; Recurrence; Tachycardia, Ventricular; Time Factors; Treatment Outcome; Ventricular Fibrillation	2017
Vagal Stimulation Facilitates Improving Effects of Ranolazine on Cardiac Function in Rats with Chronic Ischemic Heart Failure. Current molecular medicine, 2018, Volume: 18, Issue:1 Topics: Animals; Chronic Disease; Cytokines; Disease Models, Animal; Heart Failure; Male; Myocardial Ischemia; Nerve Tissue Proteins; Norepinephrine; Ranolazine; Rats; Rats, Sprague-Dawley; Vagus Nerve Stimulation; Ventricular Function, Left	2018
Arrhythmogenic cardiac alternans in heart failure is suppressed by late sodium current blockade by ranolazine. Heart rhythm, 2019, Volume: 16, Issue:2 Topics: Animals; Arrhythmias, Cardiac; Calcium; Disease Models, Animal; Dogs; Heart Conduction System; Heart Failure; Myocytes, Cardiac; Optical Imaging; Ranolazine; Sodium Channel Blockers	2019
Ranolazine prevents pressure overload-induced cardiac hypertrophy and heart failure by restoring aberrant Na Journal of cellular physiology, 2019, Volume: 234, Issue:7 Topics: Animals; Calcium; Cardiomegaly; Cardiovascular Agents; Cell Line; Fibrosis; Heart Failure; Hypertension; Male; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; Random Allocation; Ranolazine; Sodium	2019
Role of late sodium current as a potential arrhythmogenic mechanism in the progression of pressure-induced heart disease. Journal of molecular and cellular cardiology, 2013, Volume: 61 Topics: Acetanilides; Action Potentials; Animals; Arrhythmias, Cardiac; Blood Pressure; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cardiomegaly; Cells, Cultured; Female; Heart Failure; Heart Ventricles; Mice; Mice, Inbred C57BL; NAV1.1 Voltage-Gated Sodium Channel; Patch-Clamp Techniques; Peptides; Piperazines; Ranolazine; Sodium; Sodium Channel Blockers; Tetrodotoxin	2013
Inhibition of the late sodium current slows t-tubule disruption during the progression of hypertensive heart disease in the rat. American journal of physiology. Heart and circulatory physiology, 2013, Oct-01, Volume: 305, Issue:7 Topics: Acetanilides; Animals; Calcium Channels, L-Type; Calcium Signaling; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Heart Failure; Hypertension; Hypertrophy, Left Ventricular; Male; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Piperazines; Ranolazine; Rats; Rats, Inbred SHR; Ryanodine Receptor Calcium Release Channel; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Sodium; Sodium Channel Blockers; Sodium Channels; Sodium-Calcium Exchanger; Time Factors; Ultrasonography	2013
Ranolazine effectively suppresses atrial fibrillation in the setting of heart failure. Circulation. Heart failure, 2014, Volume: 7, Issue:4 Topics: Acetanilides; Action Potentials; Animals; Atrial Fibrillation; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Electrocardiography; Enzyme Inhibitors; Follow-Up Studies; Heart Atria; Heart Conduction System; Heart Failure; Heart Ventricles; Myocytes, Cardiac; Patch-Clamp Techniques; Piperazines; Ranolazine; Sodium Channel Blockers	2014
Long-term administration of ranolazine attenuates diastolic dysfunction and adverse myocardial remodeling in a model of heart failure with preserved ejection fraction. International journal of cardiology, 2016, Aug-15, Volume: 217 Topics: Animals; Cardiovascular Agents; Disease Models, Animal; Drug Administration Schedule; Heart Failure; Humans; Hypertension; Male; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Ranolazine; Rats; Rats, Inbred Dahl; Signal Transduction; Stroke Volume; Treatment Outcome; Ventricular Remodeling	2016
Ranolazine for the treatment of pulmonary hypertension associated with heart failure with preserved ejection fraction: A pilot study. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2016, Volume: 35, Issue:11 Topics: Aged; Cardiovascular Agents; Female; Heart Failure; Humans; Hypertension, Pulmonary; Male; Pilot Projects; Ranolazine; Stroke Volume	2016
Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure. American journal of physiology. Heart and circulatory physiology, 2008, Volume: 295, Issue:5 Topics: Acetanilides; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiotonic Agents; Disease Models, Animal; Disease Progression; Dogs; Drug Therapy, Combination; Enalapril; Heart Failure; Metoprolol; Myocardium; Piperazines; Proteins; Ranolazine; Ventricular Dysfunction, Left; Ventricular Remodeling	2008
Cardiomyocytes from postinfarction failing rat hearts have improved ischemia tolerance. American journal of physiology. Heart and circulatory physiology, 2009, Volume: 296, Issue:3 Topics: Acetanilides; Adenosine Triphosphate; Animals; Calcium; Cell Death; Cell Hypoxia; Cells, Cultured; Disease Models, Animal; Heart Failure; L-Lactate Dehydrogenase; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocytes, Cardiac; Oxygen; Piperazines; Potassium; Ranolazine; Rats; Rats, Wistar; Rubidium Radioisotopes; Sodium; Sodium Channel Blockers; Sodium-Calcium Exchanger; Sodium-Potassium-Exchanging ATPase; Time Factors	2009
Late sodium current contributes to diastolic cell Ca2+ accumulation in chronic heart failure. The journal of physiological sciences : JPS, 2010, Volume: 60, Issue:4 Topics: Acetanilides; Action Potentials; Animals; Calcium; Computer Simulation; Dogs; Heart Failure; Myocytes, Cardiac; Piperazines; Ranolazine; Sodium; Sodium Channel Blockers; Tetrodotoxin	2010
Ranolazine is effective for acute or chronic ischemic dysfunction with heart failure. Journal of the American College of Cardiology, 2010, Aug-31, Volume: 56, Issue:10 Topics: Acetanilides; Cardiomyopathies; Enzyme Inhibitors; Heart Failure; Humans; Myocardial Ischemia; Piperazines; Ranolazine	2010
Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. Clinical chemistry, 2012, Volume: 58, Issue:1 Topics: Acetanilides; Acute Coronary Syndrome; Aged; Biomarkers; Cardiovascular Diseases; Electrocardiography; Female; Heart Failure; Hemodynamics; Humans; Inflammation; Interleukin-1 Receptor-Like 1 Protein; Male; Natriuretic Peptide, Brain; Piperazines; Prognosis; Randomized Controlled Trials as Topic; Ranolazine; Receptors, Cell Surface; Risk Assessment	2012
Ranolazine-induced severe bladder hypotonia. The Annals of pharmacotherapy, 2012, Volume: 46, Issue:9 Topics: Acetanilides; Aged, 80 and over; Angina Pectoris; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Enzyme Inhibitors; Heart Failure; Humans; Male; Muscle Hypotonia; Piperazines; Ranolazine; Urinary Bladder Diseases; Urinary Retention	2012
Pathological role of serum- and glucocorticoid-regulated kinase 1 in adverse ventricular remodeling. Circulation, 2012, Oct-30, Volume: 126, Issue:18 Topics: Acetanilides; Animals; Cardiomegaly, Exercise-Induced; Cardiomyopathy, Dilated; Consensus Sequence; Disease Models, Animal; Electrocardiography; Enzyme Induction; Heart Failure; Humans; Hypertension; Immediate-Early Proteins; Ion Channel Gating; Mice; Mice, Inbred C57BL; Mice, Transgenic; NAV1.5 Voltage-Gated Sodium Channel; Phosphatidylinositol 3-Kinases; Phosphorylation; Piperazines; Protein Interaction Mapping; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Ranolazine; Sodium Channel Blockers; Tachycardia, Ventricular; Ventricular Remodeling	2012
Further insights into the underlying electrophysiological mechanisms for reduction of atrial fibrillation by ranolazine in an experimental model of chronic heart failure. European journal of heart failure, 2012, Volume: 14, Issue:12 Topics: Acetanilides; Acetylcholine; Animals; Atrial Fibrillation; Disease Models, Animal; Electrocardiography; Enzyme Inhibitors; Female; Heart Conduction System; Heart Failure; Isoproterenol; Piperazines; Rabbits; Ranolazine; Signal Processing, Computer-Assisted	2012
Ranolazine for atrial fibrillation: buy one get three beneficial mechanisms! European journal of heart failure, 2012, Volume: 14, Issue:12 Topics: Acetanilides; Animals; Atrial Fibrillation; Enzyme Inhibitors; Female; Heart Failure; Piperazines; Ranolazine	2012
New insights into the beneficial electrophysiologic profile of ranolazine in heart failure: prevention of ventricular fibrillation with increased postrepolarization refractoriness and without drug-induced proarrhythmia. Journal of cardiac failure, 2012, Volume: 18, Issue:12 Topics: Acetanilides; Action Potentials; Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Electrocardiography; Heart Failure; Piperazines; Rabbits; Ranolazine; Refractory Period, Electrophysiological; Sotalol; Ventricular Fibrillation	2012
Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure. Circulation research, 2002, Aug-23, Volume: 91, Issue:4 Topics: Acetanilides; Animals; Cardiotonic Agents; Chronic Disease; Coronary Circulation; Disease Models, Animal; Dobutamine; Dogs; Drug Administration Schedule; Fatty Acids, Nonesterified; Glucose; Heart; Heart Failure; Heart Rate; Lactic Acid; Myocardium; Oxygen Consumption; Piperazines; Ranolazine; Stroke Volume; Time Factors; Treatment Outcome; Ventricular Dysfunction, Left	2002
Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure. Journal of cardiac failure, 2002, Volume: 8, Issue:6 Topics: 3-Hydroxyacyl CoA Dehydrogenases; Acetanilides; Acetyl-CoA C-Acyltransferase; Animals; Carbon-Carbon Double Bond Isomerases; Chronic Disease; Disease Models, Animal; Dogs; Enoyl-CoA Hydratase; Enzyme Inhibitors; Heart Failure; Heart Ventricles; Hemodynamics; Injections, Intravenous; Models, Cardiovascular; Piperazines; Racemases and Epimerases; Radiography; Ranolazine; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left	2002
Cardiac metabolism as a target for the treatment of heart failure. Circulation, 2004, Aug-24, Volume: 110, Issue:8 Topics: Acetanilides; Animals; Dogs; Energy Metabolism; Epoxy Compounds; Fatty Acids; Forecasting; Glucagon; Glucagon-Like Peptide 1; Glucose; Heart Failure; Humans; Insulin Resistance; Myocardium; Peptide Fragments; Piperazines; Protein Precursors; Ranolazine; Recombinant Proteins	2004
New drugs for prevention, relief. How you might benefit if 3 medications win FDA approval. Heart advisor, 2005, Volume: 8, Issue:10 Topics: Acetanilides; Angina Pectoris; Benzazepines; Heart Failure; Humans; Obesity; Piperazines; Piperidines; Pyrazoles; Ranolazine; Rimonabant; Tolvaptan	2005
Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. Journal of cardiovascular electrophysiology, 2006, Volume: 17 Suppl 1 Topics: Acetanilides; Action Potentials; Animals; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Enzyme Inhibitors; Heart Failure; Heart Ventricles; Ion Channel Gating; Membrane Potentials; Myocardial Contraction; Myocytes, Cardiac; Piperazines; Ranolazine; Sodium; Sodium Channels; Ventricular Dysfunction, Left	2006
Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts--role of late sodium current and intracellular ion accumulation. Journal of molecular and cellular cardiology, 2008, Volume: 45, Issue:1 Topics: Acetanilides; Adult; Aged; Animals; Calcium; Cardiotonic Agents; Cnidarian Venoms; Diastole; Enzyme Inhibitors; Female; Heart Failure; Heart Ventricles; Humans; Ion Transport; Male; Middle Aged; Myocardial Contraction; Myocardium; Myocytes, Cardiac; Piperazines; Rabbits; Ranolazine; Sodium	2008
Another calcium paradox in heart failure. Journal of molecular and cellular cardiology, 2008, Volume: 45, Issue:1 Topics: Acetanilides; Adult; Aged; Animals; Calcium; Cardiotonic Agents; Cnidarian Venoms; Diastole; Enzyme Inhibitors; Female; Heart Failure; Heart Ventricles; Humans; Ion Transport; Male; Middle Aged; Myocardial Contraction; Myocardium; Myocytes, Cardiac; Piperazines; Rabbits; Ranolazine; Sodium	2008